%PDF-1.4
%
38 0 obj
<>
endobj
40 0 obj
<>stream
2005-10-07T13:48:18Z
QuarkXPress(tm) 6.5
2024-03-28T06:21:01-07:00
2024-03-28T06:21:01-07:00
QuarkXPress(tm) 6.5
%%DocumentProcessColors: Black
%%EndComments
uuid:1d9b216c-1dd2-11b2-0a00-3c0927bd3700
uuid:1d9b216f-1dd2-11b2-0a00-5b0000000000
application/pdf
endstream
endobj
8 0 obj
<>]>>
endobj
33 0 obj
<>
endobj
34 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
35 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
36 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
57 0 obj
[62 0 R]
endobj
58 0 obj
<>stream
1 g
/GS0 gs
0 783 0 0 re
f
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00999 Tc 0.09399 Tw 10 0 0 10 40.5 730.3264 Tm
(get involved in research at the beginning of a project rather)Tj
0 -1.2 TD
(t)Tj
0.12 Tw [(han merely endorsing it at the end. )57 (A)-305 (further aspect of the)]TJ
-0.026 Tw T*
(newsletter will be to enable Patient Research Partners to share)Tj
0.08 Tw T*
[(their experiences, primarily focusing on experiences in rela)3 (-)]TJ
0.02499 Tw T*
(tion to involvement in and contribution to research.)Tj
0 Tc 0.007 Tw 1.2 -1.16 Td
[(Patients\325)-182 (direct experience of their illness and their expe)2 (-)]TJ
0.119 Tw -1.2 -1.15999 Td
(rience of being subjects in research projects provide them)Tj
0.106 Tw 0 -1.16 TD
(with a unique insight in areas of applied clinical research.)Tj
0.00101 Tw T*
(One group \(J. Kirwan and colleagues\) reported on how they)Tj
-0.02499 Tw T*
[(had several Patient Research Partners at their center)42 (, helping)]TJ
0.02 Tc 0.362 Tw 0 -1.16001 TD
(to develop or manage a range of research projects.)Tj
0 Tc 0.078 Tw 0 -1.16 TD
(Recognizing the fear patients may have of being unable to)Tj
0.00101 Tw T*
(contribute for a variety of reasons, they had addressed some)Tj
-0.00011 Tc T*
(of)Tj
0 Tc 0.01801 Tw 1.10125 0 Td
[(these issues by holding 2 Patient Research Partners\325)-194 (edu-)]TJ
0.02499 Tw -1.10125 -1.16 Td
(cation days, as follows.)Tj
0 -2.32001 TD
(Why Patients May Fear Involvement as Research Partners)Tj
-0.00011 Tc 0 -1.15999 TD
(\245)Tj
0 Tc 0.89982 0 Td
(Feeling that their views are not taken seriously)Tj
-0.89982 -1.16 Td
[(\245)-549.9 (Concern that they have nothing useful to contribute)]TJ
-0.00011 Tc 0 -1.16 TD
(\245)Tj
0 Tc 0.88203 0 Td
[(W)80 (orry that a lack of expertise in research will bar them )]TJ
0.21798 -1.16 Td
(from contributing )Tj
-1.10001 -1.16 Td
[(\245)-549.9 (Feeling that they may not understand the medical )]TJ
1.10001 -1.16 Td
(terms/language being used)Tj
-1.10001 -1.16 Td
[(\245)-549.9 (Concern that physical symptoms, disability)66 (, or other )]TJ
1.10001 -1.16 Td
(limitations make them unable to become involved.)Tj
0.037 Tw -1.10001 -2.32 Td
[(These included information about clinical research and dis)3 (-)]TJ
0.015 Tw T*
(cussions about how patients and researchers feel when their)Tj
0.017 Tw T*
[(relationship is changed from a clinical encounter to a work)3 (-)]TJ
0.004 Tc 0.371 Tw T*
[(ing meeting, then back again to a clinical encounter)58 (.)]TJ
0 Tc 0.27901 Tw T*
(Although these events were popular and useful, Patient)Tj
0.117 Tw T*
(Research Partners will require more training, support, and)Tj
0.08299 Tw T*
(financial provision if they are to fulfill their potential. )Tj
0 Tw 22.44531 0 Td
(The)Tj
-0.01601 Tw -22.44531 -1.16001 Td
(group hope to examine published work in the field and learn)Tj
-0.02901 Tw T*
[(from current initiatives in rheumatology)67 (, other areas of med)1 (-)]TJ
-0.02299 Tw T*
(icine \(e.g., cancer therapy\), the UK National Health Service,)Tj
0.343 Tw T*
(and granting agencies \(e.g., the UK Medical Research)Tj
-0.00301 Tw T*
[(Council\). Funding for a project combining this with qualita)2.7 (-)]TJ
0.015 Tw T*
(tive exploration of patient research partner needs is actively)Tj
0.02499 Tw 0 -1.15999 TD
(being sought.)Tj
ET
BT
/T1_1 1 Tf
0 Tw 10 0 0 10 304.5 730.3264 Tm
(Discussion)Tj
ET
BT
/T1_0 1 Tf
0.02901 Tw 10 0 0 10 304.5 718.7264 Tm
(The research agenda that was developed in 2002 during the)Tj
0.117 Tw T*
[(Patient Perspective )19 (W)80 (orkshop at OMERACT)-349 (6 has stimu-)]TJ
0.011 Tw 0 -1.16 TD
[(lated new work in several areas. )19 (The present article is limit)2 (-)]TJ
0.073 Tw T*
(ed to progress made by those able to attend and contribute)Tj
T*
(to)Tj
0.131 Tw 1.15876 0.00001 Td
[(the 2004 )18 (W)80 (orkshop. )18 (The most obvious areas of impor-)]TJ
0.09 Tw -1.15876 -1.16 Td
[(tance are the measurement of fatigue and the use of infor)3 (-)]TJ
-0.004 Tw T*
(mation technology in outcome assessment, the development)Tj
0.19299 Tw 0 -1.15999 TD
[(of the patient glossary)66 (, and improvements in the support)]TJ
0.069 Tw 0 -1.16001 TD
[(provided to Patient Research Partners. In addition, interna)2 (-)]TJ
-0.022 Tw 0 -1.16 TD
(tional attention has been drawn to the need to make sure that)Tj
0.237 Tw T*
[(the patient\325)56 (s perspective is not lost among the technical)]TJ
-0.015 Tw 0 -1.16001 TD
[(expertise of rheumatology)66 (. Some areas of the research agen)1 (-)]TJ
-0.005 Tw 0 -1.15999 TD
[(da are still being taken forward, and progress will emer)19 (ge in)]TJ
0.071 Tw 0 -1.16 TD
(the coming years. In the meantime, the Patient Perspective)Tj
-0.01801 Tw T*
[(W)80 (orkshop at OMERACT)-214 (7 will be able to build on what has)]TJ
0.02499 Tw T*
[(been achieved so far)56 (.)]TJ
ET
BT
/T1_1 1 Tf
0 Tw 10 0 0 10 304.5 521.5266 Tm
(REFERENCES)Tj
ET
BT
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 311.7 511.9266 Tm
[(1.)-600 (Kirwan J, Heiber)18 (g )17 (T)74 (, Hewlett S, et al. Outcomes from the Patient)]TJ
1.35 -1.2 Td
[(Perspective workshop at OMERACT)-257 (6. J Rheumatol )]TJ
0 Tw 0 -1.2 TD
(2003;30:868-72.)Tj
0.02499 Tw -1.35 -1.2 Td
[(2.)-600 (Kirwan JR, Hewlett S, Heiber)18 (g )17 (T)75 (, et al. Incorporating the patient)]TJ
1.35 -1.2 Td
(perspective into outcome assessment in rheumatoid )Tj
0 -1.19999 TD
[(arthritis \321 progress at OMERACT)-257 (7. J Rheumatol 2005;32:2250-6.)]TJ
0 Tw -1.35 -1.2 Td
(3.)Tj
0.02499 Tw 1.35 0 Td
[(Carr )55 (A, Hewlett S, Hughes R, et al. Rheumatology outcomes: the)]TJ
0 Tw 0 -1.2 TD
[(patient\325)56 (s)]TJ
0.02499 Tw 3.66293 0 Td
(perspective. J Rheumatol 2003;30:880-3.)Tj
-5.01293 -1.20001 Td
[(4.)-600 (Ahlmen M, Nordenskiold U, )54 (Archenholtz B, et al. Rheumatology)]TJ
1.35 -1.2 Td
[(outcomes: the patient\325)56 (s perspective. )56 (A)-220 (multicentre focus group)]TJ
T*
(interview study of Swedish rheumatoid arthritis patients.)Tj
T*
(Rheumatology Oxford 2005;44:105-10. )Tj
0 Tw -1.35 -1.2 Td
(5.)Tj
0.02499 Tw 1.35 0 Td
[(Minnock P)111 (, FitzGerald O, Bresnihan B. )18 (W)80 (omen with established)]TJ
T*
(rheumatoid arthritis perceive pain as the predominant impairment of)Tj
T*
(health status. Rheumatology Oxford 2003;41:995-1000.)Tj
-1.35 -1.2 Td
[(6.)-600 (Katz P)111 (, editor)55 (. Patient outcomes in rheumatology: a review of )]TJ
1.35 -1.19999 Td
[(measures. )55 (Arthritis Care Res 2003;49 Suppl.)]TJ
0 Tw -1.35 -1.2 Td
[(7.)-600 (Kvien )]TJ
0.02499 Tw 4.05078 0 Td
(TK, Mowinckel P)Tj
-0.00011 Tc 7.13203 0 Td
(,)Tj
0 Tc 0 Tw 0.52483 0 Td
[(Heiber)18.4 (g)]TJ
0.02499 Tw 3.45974 0 Td
[(T)74 (, et al. Performance of health)]TJ
-13.81738 -1.20002 Td
[(status)-275 (measures with a pen-based personal digital assistant. )56 (Ann)]TJ
T*
[(Rheum Dis 2005 )55.6 (Apr 20; Epub ahead of print. )]TJ
ET
0 0 0 1 K
39.968 72 m
544.968 72 l
S
0 0 0 0 k
480.79 49.2 64.178 15.665 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tw 8 0 0 8 527.968 51.9343 Tm
(2249)Tj
ET
0 0 0 0 k
40.032 50.335 203 15.6649 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 41.032 53.0695 Tm
[(Kirwan, et al: Pr)37 (ogr)36 (ess in RA)-257 (outcome assessment)]TJ
ET
0 0 0 0 k
/GS2 gs
87.75 67.584 407.5 10.833 re
f
BT
0 0 0 1 k
/GS1 gs
/T1_3 1 Tf
0.033 Tc 0.028 Tw 8 0 0 8 93.7944 70.9608 Tm
(Personal non-commercial use only)Tj
0.03329 Tc 16.41141 0.00001 Td
(.)Tj
0.033 Tc 0.63234 0.00001 Td
[(The Journal of Rheumatology Copyright )-3 (\251)-339 (2005. )54 (All rights reserved.)]TJ
ET
0.5 w
87.75 67.584 407.5 10.833 re
h
S
BT
/T1_0 1 Tf
0 Tc 0.02499 Tw 12 0 0 12 179.0737 251.4605 Tm
[(Articles presented at OMERACT)-257 (7 Conference)]TJ
0 Tw 1.82671 -1.2 Td
[(Asilomar)40.8 (,)]TJ
0.02499 Tw 4.20606 0 Td
(California, May 8\32012, 2004)Tj
ET
BT
/T1_1 1 Tf
0 Tw 10 0 0 10 41 219.1616 Tm
(Modules)Tj
ET
BT
/T1_0 1 Tf
-0.00011 Tc 10 0 0 10 41 207.1617 Tm
(\245)Tj
0 Tc 0.02499 Tw 0.89975 0 Td
[(Minimal Disease )55 (Activity for RA)]TJ
-0.00011 Tc -0.89975 -1.2 Td
(\245)Tj
0 Tc 0.8996 0 Td
[(OMERACT)-240 (W)80 (orking Group on Safety)]TJ
-0.00011 Tc -0.8996 -1.2 Td
(\245)Tj
0 Tc 1.11993 0.00001 Td
(Ankylosing Spondylitis: Imaging)Tj
ET
BT
/T1_1 1 Tf
0 Tw 10 0 0 10 41 159.1618 Tm
[(W)55 (orkshops)]TJ
ET
BT
/T1_0 1 Tf
-0.00011 Tc 10 0 0 10 41 147.1618 Tm
(\245)Tj
0 Tc 0.02499 Tw 0.8998 0 Td
(Patient Perspective in Outcome Measurement)Tj
-0.00011 Tc -0.8998 -1.2 Td
(\245)Tj
0 Tc 0.89975 0 Td
(Outcome Measures in Psoriatic )Tj
0 Tw 12.81814 0 Td
(Arthritis)Tj
-0.00011 Tc -13.71788 -1.19999 Td
(\245)Tj
0 Tc 0.02499 Tw 0.89978 0 Td
(Outcome Measures in Fibromyalgia Syndrome)Tj
ET
BT
/T1_1 1 Tf
10 0 0 10 305 220.1616 Tm
[(Special Inter)18 (est Gr)18 (oups)]TJ
ET
BT
/T1_0 1 Tf
0 Tw 10 0 0 10 305 208.1616 Tm
[(\245)-549.9 (Concomitant )-6.1 (Therapies)]TJ
-0.00011 Tc T*
(\245)Tj
0 Tc 0.8997 0 Td
(Gout)Tj
-0.00011 Tc -0.8997 -1.2 Td
(\245)Tj
0 Tc 0.02499 Tw 0.8997 0 Td
(Measurement of Erosion Size/JSN)Tj
-0.00011 Tc -0.8997 -1.2 Td
(\245)Tj
0 Tc 0.89985 0 Td
(Magnetic Resonance Imaging)Tj
-0.00011 Tc -0.89984 -1.19998 Td
(\245)Tj
0 Tc 0.8998 0 Td
(Psycoeducational Self-Management Interventions)Tj
-0.00011 Tc -0.8998 -1.2 Td
(\245)Tj
0 Tc 0.89984 0 Td
[(Reconciling Subject Dif)20 (ferences in RCT)]TJ
-0.00011 Tc -0.89984 -1.20001 Td
(\245)Tj
0 Tc 0 Tw 0.89982 0 Td
[(Synovial )-6.6 (T)35 (issue)]TJ
-0.00011 Tc -0.89982 -1.19998 Td
(\245)Tj
0 Tc 0.02499 Tw 0.89977 0 Td
(Ultrasound Imaging)Tj
-0.00011 Tc -0.89977 -1.2 Td
(\245)Tj
0 Tc 0.88203 0.00001 Td
(V)Tj
0 Tw 0.61109 0.00001 Td
(asculitis)Tj
ET
BT
/T1_0 1 Tf
0.02499 Tw 9.7 0 0 10 101.1263 97.1616 Tm
(Part 1 appeared in the October issue and Part 3 will appear in the Decem\
ber issue of )Tj
ET
BT
/T1_2 1 Tf
9.7 0 0 10 434.0927 97.1616 Tm
(The Journal.)Tj
ET
39 266 m
544.032 266 l
S
BT
0 g
/GS3 gs
/T1_4 1 Tf
0 Tw 10 0 0 10 513 8 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
24 0 obj
<>
endobj
32 0 obj
<>
endobj
12 0 obj
<>
endobj
16 0 obj
<>
endobj
46 0 obj
<>
endobj
13 0 obj
<>
endobj
15 0 obj
<>
endobj
14 0 obj
<>stream
JCNHPS+Helvetica F #!
?
? V_5.0d8e2 1990-99 Apple Computer Inc. 1981 Linotype AG 1990-91 Type Solutions Inc.Helvetica 1 F S T P O B M D N J V Z 5 I + G 3 U H $ Q " W E ! " j Y"$3g3r4u
u
35rCjL`CC[b ZyC.):TIG ǁvdB }ag`¼ܞίE~\takgSM@l-]/#m ڀsg@1,nL9`4\M=H,IRd#
CoM?
Ai 8#4ShE_4Wdp]ts\jfb>v^D 51_5HZort#gxz|sh]
R<^r|}m+?xUpZ(L:'qBlnYzNk8mO}H ߋjHcVJ7KC |nV$,X&,?}Чª̔Γמ%Y<'ZnPM|L#3H g]r [I[9'`jt_uɋÛtw{Zd=<%mS2<Τ7Wmt{}noybWCHH:+MM
_pHz<C3j5*)W4:k<)Cl3H־rYjVBOKq
!_#|O]}oW)$ U;spnWF6@GwPbhsee`V,FWKK'`K`K}Ll0BT%X-ާ2>H"9rO^5S4Okz[
` x[TkvrrHvvL8dd*L0[:CnneneXC^C}>H%)nPfR<7MC|mT!/4CxeQiuee`UH
JYg7w^BjFg!+F4O"G$pSН:E<)")0F0H"F|8lut:lNath~U@`zweD"WLO'5C[
YǂyjK+rrlvÄY?SD=FB/<:<Z%'%Y,<"pxzjt}r~O?'?J}]h_,|;'$rR`*1Z4KbqzKpA'{c!%ڟb:hhiLB73|>nI V0Q9!ޤ=n?@+REmg-$#W?Z1 /Vw*m=bP>S'Ӌ58W\QVte|}
6\rߤP
NA6!<fE+HZiwhy܋;}UU9DwNc`pdfgZ"C
n?P?/!K˙ǧѶ6'
U(RJDw.MG?pCHC(M)CDN*
(MCC(
N*DC)(Bs
_C@####B__BD####C@__B#$$#BC__B$##$B_}k>ҵŰ̯
źܳm%h܋YF=_